-
Lung Cancer: The largest mid-DLL3 epidemiological study found that DLL3 expression was not associated with prognosis in patients with small cell lung cancer.
Time of Update: 2020-08-06
the study collected independent cancer samples from 1,073 patients, aged 66 and 64% male.
the combination of the samples collected, DLL3 cytological and histological expression consistency was 88% (n-17).
DLL3 expression remained stable during treatment, consistent with available clinical trial data.
-
Scand Immun Jol: Anti-p53 antiantibodies in the blood as a diagnostic biomarker for colorectal cancer.
Time of Update: 2020-08-06
serum anti-p53 self-antibody can potentially help distinguish BETWEEN CRC and a healthy control group or benign disease, but due to low sensitivity, it should be used in combination with other indicators.
-
Asalya's application for a new drug in China has been given priority review by AstraZeneca for the treatment of non-small cell lung cancer.
Time of Update: 2020-08-06
Savolitinib is a MET receptor tyrosine kinase inhibitor developed by Huang Pharma and AstraZeneca to treat non-small cell lung cancer (NSCLC), the first selective MET inhibitor in China, to treat interstitial epithelial transtrother conversion factor (MET) No. 14 exosome jump mutation.
-
Early experience in the treatment of malignant gliomas by proton heavy ion particles.
Time of Update: 2020-08-06
Conclusion Finally, the authors point out that the 18-month OS rate and PFS rate were 72.8% and 59.8% in patients with HGG treatment with a dose of 60Gyin in combination with dymomine, respectively; , proton heavy ion particle radiotherapy is a safe and potentially effective means of treating high-level gliomas.
-
Science: Tumor stem cell-driven positive feedback loops may be a new target for cancer treatment.
Time of Update: 2020-08-06
Tumor initiating cells , or TICs for short , are tumor stem cells , a class of tumor cells with self-renewing , cloning tumor generation capabilities and cloning long-term proliferation potential , fo
-
Piqray, the first and only drug targeting PIK3CA mutant breast cancer, has been approved in Europe.
Time of Update: 2020-08-06
Novartis announced that the European Commission (EC) has approved the combination of Piqisib with the fluorois group for the treatment of male patients with local lysatary advanced or metastatic breast cancer who are positive in hormone receptors and human epidermal growth factor receptor 2 negative (HR/HER2-), PIK3CA mutations, progression of disease after endocrine monodrug treatment, and postmenopausal female patients.
-
Clin Cancer Res: CLL patients can also benefit from BTK inhibition when they deactivate Vinacra.
Time of Update: 2020-08-06
results: 4% and 96% of CLL patients discontinued in Vinacra, respectively, in the first-line and recurrence/difficulty background.
Conclusion: For patients with BTK primary treatment, high ORR and long-lasting remission can be obtained with covalent combination BTKIs treatment.
-
Medicine: Panizumatoseusupplement therapy can improve the objective response of colorectal cancer patients with WT KRAS to some extent, but it can increase the incidence of adverse events.
Time of Update: 2020-08-06
, the results show that panizumatoscopy supplementation therapy can improve the objective response of colorectal cancer patients with WT KRAS, but will lead to an increase in level 3 and 4 adverse events.
-
The FDA approved the Monjuvi (tafasitamab-cxix) joint lying to treat relapse diffuse large B-cell lymphoma.
Time of Update: 2020-08-06
Pharmaceutical companies MorphoSys and Incyte announced today that the U.S. Food and Drug Administration (FDA) has approved a combination of Monjuvi ® (tafasitamab-cxix) to treat patients with recurrent or refractable diffuse large B-cell lymphoma (DLBCL) that are not suitable for autologous stem cell transplantation (ASCT).
-
Protein Cell: Jiang Hai/Zhang Lei team-finding new primary cancer gene and hippo pathway new regulatory factor SHANK2.
Time of Update: 2020-08-06
In addition to SHANK2, there are some potential new primary cancer genes in the remaining chromosome amplification segments of the tumor.
-
Innovative treatment for bladder cancer in China! Zilu Pharma has reached a $35 million agreement with Sesen Bio to bring Vicinium to Greater China!
Time of Update: 2020-08-06
(4) bladder removal time: FDA guidelines state that BCG non-answerNMIBC treatment goal is to avoid bladder removal, so bladder removal time is a key secondary endpoint, the results show that using Kaplan-Meier method analysis, estimated that 75% of patients remained bladder-free for 2.5 years, 88% of respondents remained without a bladder for 3 years.
-
Patienty: Exposure to blue light at night increases the risk of colorectal cancer.
Time of Update: 2020-08-06
A team led by the Barcelona-based Institute for Global Health (ISGlobal), supported by the la Caixa Foundation, conducted the first study of the relationship between night-time exposure to outdoor artificial light and colorectal cancer.
-
Oncogene: The Chango team reveals new targets for tumor therapy targeting DNA replication pressure.
Time of Update: 2020-08-06
therefore, S/G2-specific activation of RNR is realized through RRM1 phosphorylation, which ensures sufficient supply of dNTPs raw materials in the DNA replication process, and provides a new molecular mechanism for DNA replication fidelity and genomic stability.
-
Clin Cancer Res: Aparuamine combined with acetaminophen and pernison treatment metastatic deifiable prostate cancer!
Time of Update: 2020-08-06
no significant pharmacokinetic interactions were observed between abitron and Aparuamines; this study supports the treatment of mCRPC patients with this research protocol.
-
PD-L1 Single Anti-Bavencio plus Asitini: Recommended by NICE in the UK as a first-line treatment for advanced kidney cancer.
Time of Update: 2020-08-06
The National Institute for Health and Care Excellence (NICE) recommends that Merck and Pfizer's immunotherapy bavenio (avelumib) be combined with Inlyta (axinitib) for first-line treatment syntil-end renal cell carcinoma (RCC).
-
One article read the solution to the tumor virus therapy: tumor virus and immunity, as well as industrial development.
Time of Update: 2020-08-06
as mentioned above, local lysoma virus treatment can be done by lysicing cancer cells, releasing a large number of tumor-related antigens, and creating a pro-immune cytokine environment, which facilitates the implementation of antigen synopsis cells to achieve their function.
-
Anti-CD47 / PD-L1 Bispecific Antibody Clinical Trials: The first patient in China has entered the group.
Time of Update: 2020-08-06
Biopharmaceuticalcompany Innoventannounc today announced that the Phase I clinical trial (CIBI32A101) of recombinant anti-CD47/PD-L1 bispecific antibodies (IBI322) has officially begun and the first patients in China have entered the group.
-
Cancer: Effect of metformin in combination with cisplatin and radiotherapy to treat locally advanced head and neck squamous cell carcinoma.
Time of Update: 2020-08-04
The 5-year total survival rate (OS) for patients with locallate head and neck squamous cell carcinoma (LAHNSCC) is still 50%, emphasizing the need for improved treatment.
In this limited patient population, the overall survival rate and the non-progression survival rate are encouraging and need to be further explored in Phase 2 trials.
-
The Lancet Digital Health: AI algorithm snares prostate cancer with 98% accuracy
Time of Update: 2020-08-04
in summary, researchers at the University of Pittsburgh Medical Center reported on the development of artificial intelligence-based algorithms, external clinical validation, and deployment in routine practice, which detect, grade, and evaluate other clinically relevant tumor characteristics of digital prostate CNBs.
-
J Clin Oncol: A comparative analysis of gifitinib VS gofitinia-giniandaandaandaandaandaanda-cala-calcin chemotherapy in EGFR mutant lung cancer.
Time of Update: 2020-08-04
, the results show that adding permeitus and kappelin chemotherapy to the basis of gifitinib can significantly extend PFS and OS in NSCLC patients, but increase toxicity.
